Pα+ Psychedelic Bulletin #178: VA Funding of Lykos Phase 3 ‘Definitely a Possibility’; Alto’s Precision Psychiatry Platform Under Pressure; MAPS Boosts Funding for Mass. Psychedelics Ballot Question

Late last Friday, Lykos Therapeutics announced that it has met with the FDA regarding the future of its MDMA for PTSD program, after the agency refused to approve its New Drug Application (NDA) via an August 2024 Complete Response Letter. In a 100-word statement the company revealed that the ‘path forward’ for the program will include an additional Phase 3 trial (which the FDA had…

Source